Hikma Pharmaceuticals (LON:HIK) had its price target increased by JPMorgan Chase & Co. from GBX 1,050 ($13.72) to GBX 1,900 ($24.83) in a research report sent to investors on Tuesday. They currently have a neutral rating on the stock.
Other research analysts also recently issued reports about the company. Peel Hunt upgraded Hikma Pharmaceuticals to an add rating and lifted their target price for the stock from GBX 1,160 ($15.16) to GBX 1,950 ($25.48) in a research note on Thursday, August 16th. Numis Securities downgraded Hikma Pharmaceuticals to a hold rating and set a GBX 1,560 ($20.38) price target for the company. in a research note on Thursday, August 9th. Barclays restated an underweight rating on shares of Hikma Pharmaceuticals in a research note on Friday, August 10th. Finally, Citigroup boosted their price target on Hikma Pharmaceuticals from GBX 1,675 ($21.89) to GBX 2,100 ($27.44) and gave the company a buy rating in a research note on Monday, August 20th. Six research analysts have rated the stock with a hold rating and one has assigned a buy rating to the company. Hikma Pharmaceuticals presently has an average rating of Hold and an average price target of GBX 1,672.43 ($21.85).
Shares of LON HIK opened at GBX 1,659.50 ($21.68) on Tuesday. Hikma Pharmaceuticals has a 12 month low of GBX 814.20 ($10.64) and a 12 month high of GBX 2,346 ($30.65).
Hikma Pharmaceuticals PLC develops, manufactures, and markets a range of generic, branded, and in-licensed pharmaceutical products in solid, semi-solid, liquid, and injectable final dosage forms. It operates through three segments: Injectables, Generics, and Branded. The Injectables segment manufactures, markets, and sells generic injectable products for therapeutic categories, including anti-infective, anaesthetic, central nervous system (CNS), oncology, and pain management, as well as controlled substances and cardiovascular products.
Receive News & Ratings for Hikma Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Hikma Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.